"Abatacept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.
| Descriptor ID |
D000069594
|
| MeSH Number(s) |
D12.776.124.790.651.114.580.225 D12.776.377.715.548.114.580.225
|
| Concept/Terms |
CTLA-4-Ig- CTLA-4-Ig
- Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin
- Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin
- CTLA4-Ig
- CTLA4-Ig Immunoconjugate
- CTLA4 Ig Immunoconjugate
- Immunoconjugate, CTLA4-Ig
- CTLA4-Fc
|
Below are MeSH descriptors whose meaning is more general than "Abatacept".
Below are MeSH descriptors whose meaning is more specific than "Abatacept".
This graph shows the total number of publications written about "Abatacept" by people in this website by year, and whether "Abatacept" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 5 | 5 |
| 1997 | 0 | 6 | 6 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 6 | 6 |
| 2001 | 0 | 10 | 10 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Abatacept" by people in Profiles.
-
Abatacept improves posttransplant survival and reduces endothelial injury syndromes in ß-thalassemia major. Blood Adv. 2025 Dec 23; 9(24):6370-6379.
-
Belatacept as an alternative immunosuppressive agent for bone marrow-sparing in idiopathic pulmonary fibrosis lung transplant recipients with short telomeres. J Heart Lung Transplant. 2025 Oct; 44(10):1659-1662.
-
Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation. Bone Marrow Transplant. 2025 08; 60(8):1102-1107.
-
Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression. J Nephrol. 2023 05; 36(4):1169-1174.
-
Cross-Regulation of F-Box Protein FBXL2 with T-bet and TNF-a during Acute and Chronic Lung Allograft Rejection. J Immunol. 2022 11 01; 209(9):1788-1795.
-
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. J Rheumatol. 2021 07; 48(7):1073-1081.
-
Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. Am J Transplant. 2020 12; 20(12):3620-3630.
-
Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant. 2020 10; 20(10):2675-2685.
-
Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts. Clin Transplant. 2019 06; 33(6):e13531.
-
Overview of pathophysiology and treatment of human lupus nephritis. Curr Opin Rheumatol. 2016 09; 28(5):460-7.